Effect of cyclosporine A - tempol topical gel for the treatment of alopecia and anti-inflammatory disorders

[Display omitted] Over the years, extensive research has been carried out to develop new chemical entities for hair loss treatment. Despite these efforts, the newly developed topical and oral treatments have not proven to be curative. Hair loss can result from underlying mechanisms, such as inflamma...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2023-07, Vol.642, p.123121, Article 123121
Main Authors: Palakkal, Sarin, Cortial, Angèle, Frušić-Zlotkin, Marina, Soroka, Yoram, Tzur, Tomer, Nassar, Taher, Benita, Simon
Format: Article
Language:English
Subjects:
Administration, Topical
Alopecia
Alopecia - drug therapy
Animals
Anti-Inflammatory Agents - therapeutic use
CyclosporinA
Cyclosporine - pharmacology
Female
Gel
Humans
Mice
Mice, Inbred C57BL
Nanoemulsion
Synergy
Tempol
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Over the years, extensive research has been carried out to develop new chemical entities for hair loss treatment. Despite these efforts, the newly developed topical and oral treatments have not proven to be curative. Hair loss can result from underlying mechanisms, such as inflammation and apoptosis around hair follicles. We have developed a nanoemulsion based on Pemulen gel for topical application, tentatively addressing both mechanisms. The novel formulation contains two well-known molecules: Cyclosporin A (CsA), an immunosuppressant calcineurin inhibitor, and Tempol, a potent antioxidant. The in vitro permeation study on human skin revealed that the CsA-Tempol gel formulation effectively delivered CsA into the skin's inner target layer, the dermis. The effects of the CsA-Tempol gel on hair regrowth were further demonstrated in the in vivo well-established androgenetic model induced in female C57BL/6 mice. The beneficial outcome was statistically confirmed by quantitative analysis of hair regrowth, measured by color density. The results were further supported by histology analysis. Our findings revealed a topical synergy effect, resulting in lower therapeutic concentrations of both actives unlikely to cause systemic side effects. Overall, our research suggests that the CsA-Tempol gel is a highly promising platform for treating alopecia.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2023.123121